- Molecular NameTrandolapril
- SynonymTrandolaprilum [Latin]
- Weight430.545
- Drugbank_IDDB00519
- ACS_NO87679-37-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)2.6
- pkaN/A
- LogD (pH=7, predicted)-0.67
- Solubility (experiment)1.01 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.4
- LogSw (predicted, AB/LogsW2.0)1.53
- Sw (mg/ml) (predicted, ACD/Labs)5.06
- No.of HBond Donors2
- No.of HBond Acceptors7
- No.of Rotatable Bonds10
- TPSA95.94
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn ACE inhibitor used to treat high blood pressure, it may also be used to treat other conditions.
- Absorption_value50.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability10.0
- Protein binding80.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmCleavage of the ester group of trandolapril, primarily in the liver, is responsible for conversion to trandolaprilat, the active metabolite. Seven other metabolites, resulting primarily from glucuronidation or de-esterification, have been identified.
- Half lifeTrandopril, 1.3 h (healthy individuals and patients with mild to moderate hypertension); trandolaprilat, steady state, 16 to 24 h.
- ExcretionFecal and renal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityNo data are available with respect to overdosage in humans. The oral LD50 of trandolapril in mice was 4875 mg/Kg in males and 3990 mg/Kg in females. In rats, an oral dose of 5000 mg/Kg caused low mortality (1 male out of 5; 0 females). In dogs, an oral dose of 1000 mg/Kg did not cause mortality and abnormal clinical signs were not observed. In humans the most likely clinical manifestation would be symptoms attributable to severe hypotension.
- LD50 (rat)N/A
- LD50 (mouse)N/A